Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

LY-83,583

Guanylyl cyclase inhibitor
 
ALX-550-002-M005 5 mg 84.00 USD
 
ALX-550-002-M025 25 mg 327.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: BML-CN200

Competitive inhibitor of soluble guanylyl cyclase (sGC) (IC50=2µM) and of cGMP production. Neurotoxin. Blocks antigen-induced leukotriene release and reduces platelet-endothelial cell adhesion. Blocks acethylcholine-induced vasorelaxation.

Product Specification

Alternative Name:6-(Phenylamino)-5,8-quinolinedione, 6-Anilino-5,8-quinolinedione
 
Formula:C15H10N2O2
 
MW:250.3
 
Source:Synthetic.
 
CAS:91300-60-6
 
Purity:≥95% (TLC)
 
Identity:Determined by 1H-NMR.
 
Appearance:Violet to dark red powder.
 
Solubility:Soluble in methanol, methylene chloride or diluted aqueous acid; insoluble in water.
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
ALX-550-002
Please mouse over
ALX-550-002

Product Literature References

The effects of intracerebroventricular application of 8-Br-cGMP and LY-83,583, a guanylyl cyclase inhibitor, on sleep-wake activity in rats: A.C. Ribeiro & L. Kapas; Brain Res. 1049, 25 (2005), Abstract;
LY-83583 stimulates glucose transporter-1-mediated glucose transport independent of changes in cGMP levels: R.K. Prasad, et al.; Eur. J. Pharmacol. 366, 101 (1999), Abstract;
Nitric oxide stimulates cGMP production and mimics synaptic responses in metacerebral neurons of Aplysia: H.Y. Koh and J.W. Jacklet; J. Neurosci. 19, 3818 (1999), Abstract; Full Text
Guanylyl cyclase inhibition reduces contractility and decreases cGMP and cAMP in isolated rat hearts: R.E. Klabunde, et al.; Cardiovasc. Res. 37, 676 (1998), Abstract;
Histochemical detection of quinone reductase activity in situ using LY 83583 reduction and oxidation: T.H. Murphy, et al.; J. Neurochem. 70, 2156 (1998), Abstract;
Inhibition of nitric oxide formation and superoxide generation during reduction of LY83583 by neuronal nitric oxide synthase: Y. Kumagai, et al.; Eur. J. Pharmacol. 360, 213 (1998), Abstract;
A comparative study of the effects of three guanylyl cyclase inhibitors on the L-type Ca2+ and muscarinic K+ currents in frog cardiac myocytes: N. Abi-Gerges, et al.; Br. J. Pharmacol. 121, 1369 (1997), Abstract;
Modification by LY 83583 and methylene blue of relaxation induced by nitric oxide, glyceryl trinitrate, sodium nitroprusside and atriopeptin in aortae of the rat, guinea-pig and rabbit: T. Kawada, et al.; Gen. Pharmacol. 25, 1361 (1994), Abstract;
Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells: D. Beasley, et al.; J. Clin. Invest. 87, 602 (1991), Abstract;
LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase: A. Mülsch, et al.; J. Pharmacol. Exp. Ther. 247, 283 (1988), Abstract;
Pharmacologic analysis of two novel inhibitors of leukotriene (slow reacting substance) release: J.H. Fleisch, et al.; J. Pharmacol. Exp. Ther. 229, 681 (1984), Abstract;

General Literature References

LY 83583 (6-anilino-5,8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation: A. Mulsch, et al.; Naunyn-Schmiedeberg's Arch. Pharmacol. 340, 119 (1989), Abstract;
Evidence that cGMP is the mediator of endothelium-dependent inhibition of contractile responses of rat arteries to alpha-adrenoceptor stimulation: K.M. MacLeod, et al.; Mol. Pharmacol. 32, 59 (1987), Abstract;

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,